2025
IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer
Ranjan K, Rajendran B, Deen I, Costantini A, de Rodas M, Desai S, Scallo F, Gianino N, Ferrone S, Schalper K. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Molecular Cancer 2025, 24: 80. PMID: 40091029, PMCID: PMC11912681, DOI: 10.1186/s12943-025-02276-z.Peer-Reviewed Original ResearchThis study investigates IL-4's role in TAP2 downregulation as a reversible mechanism of immune evasion and resistance to immunotherapy in non-small cell lung cancer, highlighting potential therapeutic strategies to restore TAP2 expression and enhance treatment efficacy.
2018
A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.
Sarnaik A, Curti B, Davar D, Kirkwood J, Hamid O, Lutzky J, Wilson M, Kluger H, Whitman E, Phan G, Thomas S, Lewis K, Arkenau H, Chesney J, Larsen B, Gorbatchevsky I, Suzuki S, Samberg N, Fardis M. A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma. Journal Of Clinical Oncology 2018, 36: tps9595-tps9595. DOI: 10.1200/jco.2018.36.15_suppl.tps9595.Peer-Reviewed Original ResearchAutologous tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesTreatment of patientsMulticenter studyMetastatic melanomaPhase 2PatientsLymphocytesMelanoma
2013
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma
Dudley M, Gross C, Somerville R, Hong Y, Schaub N, Rosati S, White D, Nathan D, Restifo N, Steinberg S, Wunderlich J, Kammula U, Sherry R, Yang J, Phan G, Hughes M, Laurencot C, Rosenberg S. Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. Journal Of Clinical Oncology 2013, 31: 2152-2159. PMID: 23650429, PMCID: PMC3731980, DOI: 10.1200/jco.2012.46.6441.Peer-Reviewed Original ResearchConceptsYoung tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesAdoptive cell therapyCD4(+) lymphocytesCell therapyInterleukin-2High-dose IL-2 therapyAutologous tumor-infiltrating lymphocytesHigh-dose interleukin-2Infusion tumor-infiltrating lymphocytesResponse to autologous tumorTIL infusionIL-2 therapyImmunologic end pointsInterferon-gamma secretionSubgroup of patientsPeripheral blood lymphocytesResponse to treatmentLymphodepleted patientsLymphodepleting chemotherapyTIL productsTIL therapyAutologous tumorDesign trialMetastatic melanoma
2011
White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy
Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C, Committee O. White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy. Clinical Cancer Research 2011, 17: 1664-1673. PMID: 21325070, DOI: 10.1158/1078-0432.ccr-10-2272.Peer-Reviewed Original ResearchConceptsAdoptive T-cell therapyTumor-infiltrating lymphocytesAdoptive cell therapyInterleukin-2TIL therapyClinical trialsRandomized phase II/III clinical trialsExpansion of TILTumor antigen-specific T cellsHigh-dose IL-2Phase II/III clinical trialsHigh-dose interleukin-2Autologous tumor-infiltrating lymphocytesLonger progression-free survivalPhase II/IIIAntigen-specific T cellsCell therapyT cell-based therapiesTIL infusion productsClinical response rateNonrandomized clinical trialProgression-free survivalStage IV melanomaMetastatic melanoma patientsT-cell therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply